BioCentury Inc. published an article examining the litigation, implementation, and industry risks surrounding the major-favored-nation strategy, Lilly's 13th takeout of the year, and Heidi Overton's path toward FDA on the latest BioCentury This Week.
Published
Signal category
Presence & Recognition
Quote
“On the latest BioCentury This Week, BioCentury’s editors examine the litigation, implementation, and industry risks surrounding the MFN strategy, plus Lilly’s 13th takeout of the year and Heidi Overton’s path toward FDA.”
— BioCentury Inc. team
Company
- Industry
- Biotechnology Research
- Location
- San Mateo, US
- Company size
- 85 employees
BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. When you subscribe to BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry. Watch the latest episodes of The BioCentury Show on YouTube www.biocenturyyoutube.com Subscribe to the "BioCentury This Week" podcast www.biocenturypodcast.com